Cargando…
Time to Recurrence as a Prognostic Factor in Parathyroid Carcinoma
BACKGROUND: Parathyroid carcinoma (PC) is a rare and challenging disease without clearly understood prognostic factors. Adequate management can improve outcomes. Characteristics of patients treated for PC over time and factors affecting prognosis were analyzed. METHODS: Retrospective cohort study in...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10274572/ https://www.ncbi.nlm.nih.gov/pubmed/37334212 http://dx.doi.org/10.1210/jendso/bvad067 |
_version_ | 1785059763593150464 |
---|---|
author | Magnabosco, Felipe Ferraz Brescia, Marilia D’Elboux Guimarães Nascimento Júnior, Climério Pereira Massoni Neto, Ledo Mazzei Arap, Sergio Samir de Castro Junior, Gilberto Ledesma, Felipe Lourenço Ferreira Alves, Venancio Avancini Kowalski, Luiz Paulo Martin, Regina Matsunaga de Menezes Montenegro, Fabio Luiz |
author_facet | Magnabosco, Felipe Ferraz Brescia, Marilia D’Elboux Guimarães Nascimento Júnior, Climério Pereira Massoni Neto, Ledo Mazzei Arap, Sergio Samir de Castro Junior, Gilberto Ledesma, Felipe Lourenço Ferreira Alves, Venancio Avancini Kowalski, Luiz Paulo Martin, Regina Matsunaga de Menezes Montenegro, Fabio Luiz |
author_sort | Magnabosco, Felipe Ferraz |
collection | PubMed |
description | BACKGROUND: Parathyroid carcinoma (PC) is a rare and challenging disease without clearly understood prognostic factors. Adequate management can improve outcomes. Characteristics of patients treated for PC over time and factors affecting prognosis were analyzed. METHODS: Retrospective cohort study including surgically treated patients for PC between 2000 and 2021. If malignancy was suspected, free-margin resection was performed. Demographic, clinical, laboratory, surgical, pathological, and follow-up characteristics were assessed. RESULTS: Seventeen patients were included. Mean tumor size was 32.5 mm, with 64.7% staged as pT1/pT2. None had lymph node involvement at admission, and 2 had distant metastases. Parathyroidectomy with ipsilateral thyroidectomy was performed in 82.2%. Mean postoperative calcium levels were different between patients who developed recurrence vs those who did not (P = .03). Six patients (40%) had no recurrence during follow-up, 2 (13.3%) only regional, 3 (20%) only distant, and 4 (26.6%) both regional and distant. At 5 and 10 years, 79% and 56% of patients were alive, respectively. Median disease-free survival was 70 months. Neither Tumor, Nodule, Metastasis system nor largest tumor dimension (P = .29 and P = .74, respectively) were predictive of death. En bloc resection was not superior to other surgical modalities (P = .97). Time between initial treatment and development of recurrence negatively impacted overall survival rate at 36 months (P = .01). CONCLUSION: Patients with PC can survive for decades and have indolent disease course. Free margins seem to be the most important factor in initial surgery. Recurrence was common (60%), but patients with disease recurrence within 36 months of initial surgery had a lower survival rate. |
format | Online Article Text |
id | pubmed-10274572 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-102745722023-06-17 Time to Recurrence as a Prognostic Factor in Parathyroid Carcinoma Magnabosco, Felipe Ferraz Brescia, Marilia D’Elboux Guimarães Nascimento Júnior, Climério Pereira Massoni Neto, Ledo Mazzei Arap, Sergio Samir de Castro Junior, Gilberto Ledesma, Felipe Lourenço Ferreira Alves, Venancio Avancini Kowalski, Luiz Paulo Martin, Regina Matsunaga de Menezes Montenegro, Fabio Luiz J Endocr Soc Clinical Research Article BACKGROUND: Parathyroid carcinoma (PC) is a rare and challenging disease without clearly understood prognostic factors. Adequate management can improve outcomes. Characteristics of patients treated for PC over time and factors affecting prognosis were analyzed. METHODS: Retrospective cohort study including surgically treated patients for PC between 2000 and 2021. If malignancy was suspected, free-margin resection was performed. Demographic, clinical, laboratory, surgical, pathological, and follow-up characteristics were assessed. RESULTS: Seventeen patients were included. Mean tumor size was 32.5 mm, with 64.7% staged as pT1/pT2. None had lymph node involvement at admission, and 2 had distant metastases. Parathyroidectomy with ipsilateral thyroidectomy was performed in 82.2%. Mean postoperative calcium levels were different between patients who developed recurrence vs those who did not (P = .03). Six patients (40%) had no recurrence during follow-up, 2 (13.3%) only regional, 3 (20%) only distant, and 4 (26.6%) both regional and distant. At 5 and 10 years, 79% and 56% of patients were alive, respectively. Median disease-free survival was 70 months. Neither Tumor, Nodule, Metastasis system nor largest tumor dimension (P = .29 and P = .74, respectively) were predictive of death. En bloc resection was not superior to other surgical modalities (P = .97). Time between initial treatment and development of recurrence negatively impacted overall survival rate at 36 months (P = .01). CONCLUSION: Patients with PC can survive for decades and have indolent disease course. Free margins seem to be the most important factor in initial surgery. Recurrence was common (60%), but patients with disease recurrence within 36 months of initial surgery had a lower survival rate. Oxford University Press 2023-05-23 /pmc/articles/PMC10274572/ /pubmed/37334212 http://dx.doi.org/10.1210/jendso/bvad067 Text en © The Author(s) 2023. Published by Oxford University Press on behalf of the Endocrine Society. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (https://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com |
spellingShingle | Clinical Research Article Magnabosco, Felipe Ferraz Brescia, Marilia D’Elboux Guimarães Nascimento Júnior, Climério Pereira Massoni Neto, Ledo Mazzei Arap, Sergio Samir de Castro Junior, Gilberto Ledesma, Felipe Lourenço Ferreira Alves, Venancio Avancini Kowalski, Luiz Paulo Martin, Regina Matsunaga de Menezes Montenegro, Fabio Luiz Time to Recurrence as a Prognostic Factor in Parathyroid Carcinoma |
title | Time to Recurrence as a Prognostic Factor in Parathyroid Carcinoma |
title_full | Time to Recurrence as a Prognostic Factor in Parathyroid Carcinoma |
title_fullStr | Time to Recurrence as a Prognostic Factor in Parathyroid Carcinoma |
title_full_unstemmed | Time to Recurrence as a Prognostic Factor in Parathyroid Carcinoma |
title_short | Time to Recurrence as a Prognostic Factor in Parathyroid Carcinoma |
title_sort | time to recurrence as a prognostic factor in parathyroid carcinoma |
topic | Clinical Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10274572/ https://www.ncbi.nlm.nih.gov/pubmed/37334212 http://dx.doi.org/10.1210/jendso/bvad067 |
work_keys_str_mv | AT magnaboscofelipeferraz timetorecurrenceasaprognosticfactorinparathyroidcarcinoma AT bresciamariliadelbouxguimaraes timetorecurrenceasaprognosticfactorinparathyroidcarcinoma AT nascimentojuniorclimeriopereira timetorecurrenceasaprognosticfactorinparathyroidcarcinoma AT massoninetoledomazzei timetorecurrenceasaprognosticfactorinparathyroidcarcinoma AT arapsergiosamir timetorecurrenceasaprognosticfactorinparathyroidcarcinoma AT decastrojuniorgilberto timetorecurrenceasaprognosticfactorinparathyroidcarcinoma AT ledesmafelipelourenco timetorecurrenceasaprognosticfactorinparathyroidcarcinoma AT ferreiraalvesvenancioavancini timetorecurrenceasaprognosticfactorinparathyroidcarcinoma AT kowalskiluizpaulo timetorecurrenceasaprognosticfactorinparathyroidcarcinoma AT martinreginamatsunaga timetorecurrenceasaprognosticfactorinparathyroidcarcinoma AT demenezesmontenegrofabioluiz timetorecurrenceasaprognosticfactorinparathyroidcarcinoma |